Anti-CCR8 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12496342-B2
Application number	US-202318512759-A
Country	US
Kind code	B2
Filing date	Nov 17, 2023
Priority date	Jan 6, 2020
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.

First claim

What is claimed:

1 . A method of treating a subject having a tumor comprising administering to the subject an antibody or an antigen-binding portion thereof comprising a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 41 and comprising a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 43.

2 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is afucosylated.

3 . The method of claim 1 , wherein the antibody or the antigen-binding portion thereof comprises an IgG1 Fc domain.

4 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of an immunoconjugate.

5 . The method of claim 4 , wherein the immunoconjugate is an antibody-drug conjugate.

6 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of a chimeric antigen receptor (CAR).

7 . The method of claim 1 , wherein the antibody or an antigen-binding portion thereof is administered as part of a T cell receptor (TCR).

8 . The method of claim 1 , wherein the tumor is selected from Kaposi's sarcoma, leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblasts promyelocyte myelomonocytic monocytic erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, primary central nervous system lymphoma, Burkitt's lymphoma and marginal zone B cell lymphoma, Polycythemia vera Lymphoma, Hodgkin's disease, non-Hodgkin's disease, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, solid tumors, sarcomas, and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chrondrosarcoma, osteogenic sarcoma, osteosarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon sarcoma, colorectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma (HCC), hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, retinoblastoma, nasopharyngeal carcinoma, esophageal carcinoma, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system (CNS) cancer, cervical cancer, choriocarcinoma, colorectal cancers, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, intraepithelial neoplasm, kidney cancer, larynx cancer, liver cancer, lung cancer (small cell, large cell), melanoma, neuroblastoma; oral cavity cancer (for example lip, tongue, mouth and pharynx), ovarian cancer, pancreatic cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer; cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system, or a combination thereof.

9 . The method of claim 1 , wherein the tumor is refractory or relapsed.

10 . The method of claim 1 , wherein the tumor is advanced, locally advanced, or metastatic.

11 . The method of claim 1 , further comprising administering an additional anticancer agent.

12 . The method of claim 11 , wherein the additional anticancer agent is a small molecule, a polypeptide, a radiation therapy, a surgery, or a combination thereof.

13 . The method of claim 11 , wherein the additional anticancer agent comprises a chemotherapy.

14 . The method of claim 13 , wherein the chemotherapy comprises a platinum-based chemotherapy.

15 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-1 antagonist, a PD-L1 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a CD112R inhibitor, a TAM inhibitor, a STING agonist, a 4-1BB agonist, a CCL22 inhibitor, an agent that induces NK cell activation or a combination thereof.

16 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-1 antagonist.

17 . The method of claim 16 , wherein the PD-1 antagonist is selected from the group consisting of PDR001, nivolumab, pembrolizumab, pidilizumab, MEDI0680, REGN2810, TSR-042, PF-06801591, and AMP-224.

18 . The method of claim 11 , wherein the additional anticancer agent comprises a PD-L1 inhibitor.

19 . The method of claim 18 , wherein the PD-L1 inhibitor is selected from the group consisting of FAZ053, Atezolizumab, Avelumab, Durvalumab, and BMS-936559.

20 . The method of claim 11 , wherein the additional anticancer agent is Sunitinib, Cabozantinib, Axitinib, Lenvatinib, Everolimus, Bevacizumab, epacadostat, NKTR-214, Tivozanib, abexinostat, Ipilimumab, tremelimumab, Pazopanib, Sorafenib, Temsirolimus, Ramucirumab, niraparib, savolitinib, vorolanib (X-82), Regorafenib, Donafenib, Camrelizumab, pexastimogene devacirepvec, Ramucirumab, apatinib, encapsulated doxorubicin, Tivantinib, ADI-PEG 20, binimetinib, apatinib mesylate, nintedanib, lirilumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Cemiplimab-rwlc, tislelizumab, spartalizumab, or a combination thereof.

21 . The method of claim 11 , wherein the additional anticancer agent comprises a TIM-3 inhibitor.

22 . The method of claim 21 , wherein the TIM-3 inhibitor is MGB453 or TSR-022.

23 . The method of claim 11 , wherein the additional anticancer agent comprises a LAG-3 inhibitor.

24 . The method of claim 23 , wherein the LAG-3 inhibitor is selected from the group consisting of LAG525, BMS-986016, and TSR-033.

25 . The method of claim 11 , wherein the additional anticancer agent comprises a TIGIT inhibitor.

26 . The method of claim 11 , wherein the additional anticancer agent comprises a CD112R inhibitor.

27 . The method of claim 11 , wherein the additional anticancer agent comprises a TAM (Axl, Mer, Tyro) inhibitor.

28 . The method of claim 11 , wherein the additional anticancer agent comprises a 4-1BB agonist.

29 . The method of claim 11 , wherein the additional anticancer agent comprises a Tyrosine Kinase Inhibitor (TKI).

30 . The method of claim 11 , wherein the additional anticancer agent comprises a CCL2 inhibitor.

31 . The method of claim 1 , wherein the tumor is a head and neck cancer tumor.

32 . The method of claim 1 , wherein the tumor is a gastric cancer tumor.

33 . The method of claim 1 , wherein the tumor is a squamous cell carcinoma tumor.

Assignees

• Vaccinex Inc

Inventors

• Holland Pamela M
• Lake Andrew
• Dulak Austin
• Smith Ernest
• Scrivens Maria
• Harvey Caroline
• Kirk Renee
• Balch Leslie
• Das Sonia
• Wells Christopher Converse

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• C07K2317/31

  multispecific · CPC title